For research use only. Not for therapeutic Use.
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway[1].
The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals[1].
Taurodeoxycholate inhibits the binding of N-3H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC50 of 170 μM[1].
Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation[2].
Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells[2].
Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[1].
Catalog Number | M007746 |
CAS Number | 110026-03-4 |
Synonyms | sodium;2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate;hydrate |
Molecular Formula | C26H46NNaO7S |
Purity | ≥95% |
InChI | InChI=1S/C26H45NO6S.Na.H2O/c1-16(4-9-24(30)27-12-13-34(31,32)33)20-7-8-21-19-6-5-17-14-18(28)10-11-25(17,2)22(19)15-23(29)26(20,21)3;;/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33);;1H2/q;+1;/p-1/t16-,17-,18-,19+,20-,21+,22+,23+,25+,26-;;/m1../s1 |
InChIKey | OLPIZAYYAVQETM-GGPRKOIFSA-M |
SMILES | CC(CCC(=O)NCCS(=O)(=O)[O-])C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C.O.[Na+] |
Reference | [1]. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984. [2]. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21. |